CY1117908T1 - Μεθοδος αναστολης επαναρροφησης οστου - Google Patents
Μεθοδος αναστολης επαναρροφησης οστουInfo
- Publication number
- CY1117908T1 CY1117908T1 CY20161100685T CY161100685T CY1117908T1 CY 1117908 T1 CY1117908 T1 CY 1117908T1 CY 20161100685 T CY20161100685 T CY 20161100685T CY 161100685 T CY161100685 T CY 161100685T CY 1117908 T1 CY1117908 T1 CY 1117908T1
- Authority
- CY
- Cyprus
- Prior art keywords
- bone
- human
- bone resorption
- sclerostin
- measuring
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
Abstract
Η εφεύρεση απευθύνεται σε μια μέθοδο παρεμπόδισης επαναρρόφησης οστού. Η μέθοδος περιλαμβάνει χορήγηση σε έναν άνθρωπο μιας ποσότητας αναστολέα σκληροστίνης που μειώνει το επίπεδο δείκτη επαναρρόφησης οστού για τουλάχιστον 2 εβδομάδες. Η εφεύρεση παρέχει επίσης μέθοδο παρακολούθησης θεραπείας αντι-σκληροστίνης που περιλαμβάνει μέτρηση ενός ή περισσότερων επιπέδων δείκτη επαναρρόφησης οστού, χορήγηση παράγοντα σύνδεσης σκληροστίνης και στην συνέχεια, μέτρηση των επιπέδων δείκτη επαναρρόφησης οστού. Επίσης παρέχεται μέθοδος αύξησης της πυκνότητας ανόργανου του οστού, μέθοδος βελτίωσης των αποτελεσμάτων διαταραχής που σχετίζεται με οστεοκλάστη, μέθοδος θεραπείας διαταραχής που σχετίζεται με οστό με διατήρηση της οστικής πυκνότητας και μέθοδος θεραπείας διαταραχής που σχετίζεται με οστό σε έναν άνθρωπο που υποφέρει από υποασβεσταιμία ή υπερασβεσταιμία ή βρίσκεται σε κίνδυνο υποασβεσταιμίας ή υπερασβεσταιμίας, έναν άνθρωπο για τον οποίο αντενδείκνυται η θεραπεία με μια παραθυρεοειδή ορμόνη ή ανάλογο αυτής ή έναν άνθρωπο όπου αντενδείκνυται θεραπεία με δισφωσφονικό.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US97302407P | 2007-09-17 | 2007-09-17 | |
EP08832690.5A EP2195026B1 (en) | 2007-09-17 | 2008-09-17 | Anti-sclerostin antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1117908T1 true CY1117908T1 (el) | 2017-05-17 |
Family
ID=40371592
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20141100183T CY1114961T1 (el) | 2007-09-17 | 2014-03-07 | Αντισωματα αντι-σκληροστινης |
CY20161100685T CY1117908T1 (el) | 2007-09-17 | 2016-07-15 | Μεθοδος αναστολης επαναρροφησης οστου |
CY20201100823T CY1123463T1 (el) | 2007-09-17 | 2020-09-02 | Μεθοδος αναστολης επαναρροφησης οστου |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20141100183T CY1114961T1 (el) | 2007-09-17 | 2014-03-07 | Αντισωματα αντι-σκληροστινης |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20201100823T CY1123463T1 (el) | 2007-09-17 | 2020-09-02 | Μεθοδος αναστολης επαναρροφησης οστου |
Country Status (21)
Country | Link |
---|---|
US (7) | US8017120B2 (el) |
EP (5) | EP2556841B9 (el) |
JP (2) | JP5643094B2 (el) |
AR (2) | AR068471A1 (el) |
AU (1) | AU2008302313C1 (el) |
CA (2) | CA2699905C (el) |
CL (1) | CL2008002775A1 (el) |
CY (3) | CY1114961T1 (el) |
DK (4) | DK3725329T3 (el) |
ES (3) | ES2581754T3 (el) |
FI (1) | FI3725329T3 (el) |
HK (1) | HK1182017A1 (el) |
HR (3) | HRP20140153T1 (el) |
HU (2) | HUE050653T2 (el) |
LT (3) | LT3085386T (el) |
MX (1) | MX2010002971A (el) |
PL (3) | PL2195026T3 (el) |
PT (4) | PT3085386T (el) |
SI (4) | SI3085386T1 (el) |
TW (2) | TWI526222B (el) |
WO (1) | WO2009039175A2 (el) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1133558B2 (en) | 1998-11-27 | 2016-04-13 | UCB Pharma S.A. | Compositions and methods for increasing bone mineralization |
ES2586401T3 (es) * | 2003-06-16 | 2016-10-14 | Ucb Pharma S.A. | Anticuerpos específicos para la esclerostina y métodos para aumentar la mineralización ósea |
US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
US20100036091A1 (en) * | 2006-11-10 | 2010-02-11 | Amgen Inc. | Antibody-based diagnostics and therapeutics |
EP2094731A2 (en) * | 2006-11-10 | 2009-09-02 | UCB Pharma S.A. | Anti human sclerostin antibodies |
HUE060822T2 (hu) | 2006-12-29 | 2023-04-28 | Ossifi Mab Llc | Módszerek a csontnövekedés megváltoztatására SOST vagy WISE antagonista vagy agonista adásával |
CL2008002775A1 (es) | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
AR068767A1 (es) | 2007-10-12 | 2009-12-02 | Novartis Ag | Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina |
WO2009062152A1 (en) * | 2007-11-09 | 2009-05-14 | Washington University In St. Louis | Methods for measuring the metabolism of cns derived biomolecules in vivo |
EA201070740A1 (ru) * | 2007-12-14 | 2010-12-30 | Эмджен Инк. | Способ лечения перелома кости антителами против склеростина |
EP3521311A1 (en) | 2008-04-11 | 2019-08-07 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
PT3195880T (pt) | 2010-05-14 | 2020-02-21 | Amgen Inc | Formulações de anticorpos antiesclerostina de concentração elevada |
CA2813849C (en) | 2010-11-05 | 2021-06-15 | Novartis Ag | Secukinumab for use in the treatment of ankylosing spondylitis |
CA2819356C (en) | 2010-11-30 | 2023-01-24 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
KR20140017513A (ko) * | 2010-12-02 | 2014-02-11 | 워싱톤 유니버시티 | 아밀로이드 플라크 관련 증상을 치료하는 조성물과 방법 |
MX2013010011A (es) | 2011-03-01 | 2014-10-24 | Amgen Inc | Agentes de unión biespecífica. |
KR20140018315A (ko) | 2011-03-25 | 2014-02-12 | 암젠 인크 | 항스클러로스틴 항체 결정 및 이의 제제 |
CA2833289A1 (en) * | 2011-04-19 | 2012-10-26 | Amgen Inc. | Method for treating osteoporosis |
JP2014515759A (ja) | 2011-04-29 | 2014-07-03 | ノバルティス アーゲー | 扁平上皮がんを治療する方法関連出願 |
DK2739311T3 (en) * | 2011-08-04 | 2018-04-23 | Amgen Inc | Method of treating bone slit defects |
EA201490676A1 (ru) * | 2011-09-22 | 2015-02-27 | Экселиксис, Инк. | Способ лечения остеопороза |
KR20200056473A (ko) | 2011-12-28 | 2020-05-22 | 암젠 인크 | 항스클레로스틴 항체의 이용을 통한 치조골 소실의 치료 방법 |
EP2869844B2 (en) * | 2012-07-05 | 2023-06-21 | UCB Pharma S.A. | Treatment for bone diseases |
UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
WO2014118705A1 (en) | 2013-01-31 | 2014-08-07 | Novartis Ag | Methods of treating chronic kidney disease-mineral and bone disorder using sclerostin antagonists |
WO2014155278A2 (en) | 2013-03-26 | 2014-10-02 | Novartis Ag | Methods of treating autoimmune diseases using il-17 antagonists |
CA2962969C (en) | 2014-09-30 | 2023-03-21 | Washington University | Tau kinetic measurements |
MA41142A (fr) * | 2014-12-12 | 2017-10-17 | Amgen Inc | Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement |
AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
GB201604124D0 (en) | 2016-03-10 | 2016-04-27 | Ucb Biopharma Sprl | Pharmaceutical formulation |
WO2018115879A1 (en) | 2016-12-21 | 2018-06-28 | Mereo Biopharma 3 Limited | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta |
CA3047221A1 (en) | 2016-12-21 | 2018-06-28 | Mereo Biopharma 3 Limited | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta |
JP7191833B2 (ja) | 2017-01-30 | 2022-12-19 | 中外製薬株式会社 | 抗スクレロスチン抗体およびその使用 |
AU2019243595A1 (en) * | 2018-03-30 | 2020-09-17 | Amgen Inc. | C-terminal antibody variants |
GB201810746D0 (en) | 2018-06-29 | 2018-08-15 | Mereo Biopharma 3 Ltd | Use of sclerostin antagonist |
CN111658821A (zh) * | 2020-06-03 | 2020-09-15 | 深圳市百吉因生物科技有限公司 | 负载小干扰rna的胶原基骨修复材料及制备方法及在制备治疗骨质疏松骨折材料中的应用 |
Family Cites Families (116)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4331647A (en) * | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
US4376110A (en) * | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4411993A (en) * | 1981-04-29 | 1983-10-25 | Steven Gillis | Hybridoma antibody which inhibits interleukin 2 activity |
US4427115A (en) * | 1981-10-19 | 1984-01-24 | Laipply Thomas C | One piece alcohol preparation device |
USRE32011E (en) * | 1981-12-14 | 1985-10-22 | Scripps Clinic And Research Foundation | Ultrapurification of factor VIII using monoclonal antibodies |
US4543439A (en) * | 1982-12-13 | 1985-09-24 | Massachusetts Institute Of Technology | Production and use of monoclonal antibodies to phosphotyrosine-containing proteins |
US6054561A (en) * | 1984-02-08 | 2000-04-25 | Chiron Corporation | Antigen-binding sites of antibody molecules specific for cancer antigens |
DE3417525C1 (de) * | 1984-05-11 | 1986-01-09 | Matter + Siegmann Ag, Wohlen | Vorrichtung zur quantitativen und qualitativen Erfassung von kohlenwasserstoffhaltigen Schwebeteilchen in Gasen |
US4902614A (en) * | 1984-12-03 | 1990-02-20 | Teijin Limited | Monoclonal antibody to human protein C |
US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
ATE115999T1 (de) | 1987-12-15 | 1995-01-15 | Gene Shears Pty Ltd | Ribozyme. |
US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5571714A (en) | 1988-12-22 | 1996-11-05 | Celtrix Pharmaceuticals, Inc. | Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5549910A (en) * | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
US5244805A (en) | 1989-05-17 | 1993-09-14 | University Of Georgia Research Foundation, Inc. | Baculovirus expression vectors |
US5177197A (en) | 1990-02-27 | 1993-01-05 | Ludwig Institute For Cancer Research | Isolated nucleotide sequence expressing human transforming growth factor-β1-binding protein |
US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
JP3218637B2 (ja) * | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | 安定なリポソーム水懸濁液 |
EP0542810A1 (en) | 1990-08-02 | 1993-05-26 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
JP2958076B2 (ja) * | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法 |
US5877397A (en) * | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5698426A (en) * | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
JPH04141095A (ja) | 1990-10-02 | 1992-05-14 | Chemo Sero Therapeut Res Inst | 組換え抗hiv改変抗体および改変抗体の調製方法 |
US5070108A (en) * | 1990-10-12 | 1991-12-03 | Trustees Of The University Of Pennsylvania | Methods of treating osteoporosis, increasing bone mineral content and preventing the occurrence of compression fractures in a mammal |
WO1992006693A1 (en) | 1990-10-22 | 1992-04-30 | Fox Chase Cancer Center | Dna construct for providing rna therapy |
US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
RU2139351C1 (ru) | 1991-04-25 | 1999-10-10 | Чугаи Сейяку Кабусики Кайся | Н- и l-цепи моноклонального антитела рм1 (монат) к рецептору il-6r человека и их v-области, модифицированная монат, его н- и l-цепи и их v-области, cdr- последовательности, днк-последовательности |
US5807683A (en) | 1992-11-19 | 1998-09-15 | Combichem, Inc. | Combinatorial libraries and methods for their use |
US5864027A (en) * | 1993-06-07 | 1999-01-26 | Genentech, Inc. | HIV envelope polypeptides |
US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
US5453492A (en) * | 1993-07-28 | 1995-09-26 | La Jolla Cancer Research Foundation | 60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β |
US5605793A (en) * | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
US5837458A (en) * | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
AU702163B2 (en) | 1994-04-29 | 1999-02-18 | Creative Biomolecules, Inc. | Morphogenic protein-specific cell surface receptors and uses therefor |
US5738996A (en) | 1994-06-15 | 1998-04-14 | Pence, Inc. | Combinational library composition and method |
DE4427221A1 (de) | 1994-08-01 | 1996-02-08 | Gsf Forschungszentrum Umwelt | Retrovirus-induzierte Osteoklasten-Modulation für die Osteoporose-Therapie |
US5846770A (en) | 1994-11-22 | 1998-12-08 | Genetics Institute, Inc. | DNA molecules encoding human chordin |
US6057421A (en) * | 1994-11-30 | 2000-05-02 | Immpheron, Inc. | Variable heavy and light chain regions of murine monoclonal antibody 1F7 |
US5723750A (en) | 1995-01-12 | 1998-03-03 | Vanderbilt University | Transgenic plants expressing disassembly deficient viral coat proteins |
US5795587A (en) * | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
CA2220912A1 (en) * | 1995-06-05 | 1996-12-12 | Gregg A. Hastings | Human ccn-like growth factor |
US5738868A (en) * | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
JP4124486B2 (ja) * | 1996-05-22 | 2008-07-23 | ビベンティア バイオテック インコーポレイテッド | ガン細胞を特異的に検出する抗原結合フラグメント、このフラグメントをコードするヌクレオチド、ならびにガンの予防および検出のためのその使用 |
US6133426A (en) * | 1997-02-21 | 2000-10-17 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
US5989909A (en) | 1997-09-26 | 1999-11-23 | Millennium Biotherapeutics, Inc. | Huchordin and uses thereof |
US6117911A (en) * | 1997-04-11 | 2000-09-12 | Neorx Corporation | Compounds and therapies for the prevention of vascular and non-vascular pathologies |
US6278039B1 (en) | 1997-05-28 | 2001-08-21 | Axys Pharmaceuticals, Inc. | C. elegans deletion mutants |
ES2301198T3 (es) | 1997-06-12 | 2008-06-16 | Novartis International Pharmaceutical Ltd. | Polipeptidos artificiales de anticuerpos. |
US6075007A (en) | 1997-07-17 | 2000-06-13 | Regeneron Pharmaceuticals, Inc. | Modified noggin polypeptide and compositions |
AU8555798A (en) | 1997-08-01 | 1999-02-22 | Genset | 5' ests for secreted proteins expressed in muscle and other mesodermal tissues |
US6815201B2 (en) * | 1997-09-08 | 2004-11-09 | The Public Health Research Institute Of The City Of New York, Inc. | HIV-1 gp120 V1/V2 domain epitopes capable of generating neutralizing antibodies |
US6251588B1 (en) | 1998-02-10 | 2001-06-26 | Agilent Technologies, Inc. | Method for evaluating oligonucleotide probe sequences |
GB9818881D0 (en) * | 1998-08-28 | 1998-10-21 | Glaxo Group Ltd | Compounds |
US6544485B1 (en) * | 2001-01-29 | 2003-04-08 | Sharper Image Corporation | Electro-kinetic device with enhanced anti-microorganism capability |
EP1133558B2 (en) | 1998-11-27 | 2016-04-13 | UCB Pharma S.A. | Compositions and methods for increasing bone mineralization |
US20040009535A1 (en) * | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
EP1151002A4 (en) | 1999-01-29 | 2002-05-02 | Imclone Systems Inc | KDR-SPECIFIC ANTIBODIES AND USES THEREOF |
US6110462A (en) | 1999-03-03 | 2000-08-29 | The Scripps Research Institute | Enzymatic DNA molecules that contain modified nucleotides |
AU4851900A (en) | 1999-06-09 | 2000-12-28 | Genentech Inc. | Compositions and methods for the treatment of tumor |
US6197592B1 (en) * | 1999-07-15 | 2001-03-06 | Bio-Rad Laboratories, Inc. | Clinical control materials for detection of bone resorptive markers |
WO2001064885A1 (en) | 2000-03-02 | 2001-09-07 | Amgen, Inc. | Chordin-like-2 molecules and uses thereof |
US20020106650A1 (en) * | 2000-06-01 | 2002-08-08 | Paszty Christopher J. | Cystine-knot polypeptides: cloaked-2 molecules and uses thereof |
JP2004520005A (ja) | 2000-06-19 | 2004-07-08 | エフ.ホフマン−ラ ロシュ アーゲー | オステオレビン遺伝子多型性 |
CA2632702A1 (en) | 2000-09-01 | 2002-03-28 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
DK1324776T4 (en) | 2000-10-12 | 2018-05-28 | Genentech Inc | CONCENTRATED PROTEIN FORMULATIONS WITH REDUCED VISCOSITY |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
CA2374027A1 (en) * | 2001-03-13 | 2002-09-13 | The Minister Of National Defence | Cloning, expression, sequencing, and functional enhancement of monoclonal scfv antibody against venezuelan equine encephalitis virus(vee) |
DE10145772A1 (de) * | 2001-09-17 | 2003-04-10 | Bayer Cropscience Ag | DELTA·1·-Pyrroline |
US7261892B2 (en) | 2001-11-27 | 2007-08-28 | Celltech R&D Limited | Methods for diagnosis and treatment of epithelial-derived cancers |
MXPA04005416A (es) | 2001-12-06 | 2004-10-11 | Biocontrol Systems Inc | Sistema de prueba y recoleccion de muestras. |
US20030186915A1 (en) * | 2002-02-11 | 2003-10-02 | Yang Pan | Regulatory polynucleotides and uses thereof |
JP4662714B2 (ja) | 2002-03-01 | 2011-03-30 | セルテック アール アンド ディー インコーポレイテッド | 骨密度を増減させる方法 |
WO2003087763A2 (en) | 2002-04-03 | 2003-10-23 | Celltech R & D, Inc. | Association of polymorphisms in the sost gene region with bone mineral density |
FR2838379B1 (fr) | 2002-04-12 | 2005-06-24 | Valeo Climatisation | Dispositif de purification de l'air de l'habitacle d'un vehicule automobile |
US7893218B2 (en) * | 2003-06-16 | 2011-02-22 | Stowers Institute For Medical Research | Antibodies that specifically bind SOST peptides |
US20040023356A1 (en) * | 2002-06-14 | 2004-02-05 | Robb Krumlauf | Wise/Sost nucleic acid sequences and amino acid sequences |
CA2504493C (en) | 2002-11-01 | 2015-12-29 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of preventing infections from bioterrorism agents with immunostimulatory cpg oligonucleotides |
AU2003295600A1 (en) | 2002-11-14 | 2004-06-15 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
DE10255152A1 (de) | 2002-11-26 | 2004-06-03 | Von Langen Ursula Lang | Schadstoffsauger |
US7642238B2 (en) * | 2002-12-05 | 2010-01-05 | Shaughnessy John D | Molecular determinants of myeloma bone disease and uses thereof |
US20040141875A1 (en) * | 2003-01-15 | 2004-07-22 | Rajiv Doshi | System and method for treating microorganisms within motor vehicle heating, ventilation, and air conditioning units |
PT1608399E (pt) * | 2003-03-14 | 2012-04-13 | Ucb Mfg Inc | Complexo de esclerostina e noguina ou cordina, e agentes que modulam a formação do referido complexo |
JP4605799B2 (ja) | 2003-04-02 | 2011-01-05 | ダーマコン, インコーポレイテッド | Rna干渉において使用するための修飾ポリヌクレオチド |
US20050158303A1 (en) | 2003-04-04 | 2005-07-21 | Genentech, Inc. | Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations |
CU23403A1 (es) | 2003-04-23 | 2009-08-04 | Centro Inmunologia Molecular | Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores |
ES2586401T3 (es) | 2003-06-16 | 2016-10-14 | Ucb Pharma S.A. | Anticuerpos específicos para la esclerostina y métodos para aumentar la mineralización ósea |
US8461155B2 (en) | 2003-09-22 | 2013-06-11 | University Of Connecticut | Sclerostin and the inhibition of WNT signaling and bone formation |
EP1718747B1 (en) | 2004-02-06 | 2009-10-28 | Dharmacon, Inc. | Stabilized rnas as transfection controls and silencing reagents |
KR101147147B1 (ko) | 2004-04-01 | 2012-05-25 | 머크 샤프 앤드 돔 코포레이션 | Rna 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드 |
US20050267233A1 (en) | 2004-05-25 | 2005-12-01 | Joshi Ashok V | Anti-microbial handle system |
US7709611B2 (en) | 2004-08-04 | 2010-05-04 | Amgen Inc. | Antibodies to Dkk-1 |
US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
US7592429B2 (en) * | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
WO2007080129A1 (en) | 2006-01-13 | 2007-07-19 | A Chan Holding B.V. | Treatment and diagnosis of abnormal bone density with an inhibitor of the glypican-sclerostin interaction |
EP2094731A2 (en) | 2006-11-10 | 2009-09-02 | UCB Pharma S.A. | Anti human sclerostin antibodies |
US20100036091A1 (en) | 2006-11-10 | 2010-02-11 | Amgen Inc. | Antibody-based diagnostics and therapeutics |
US20080120672A1 (en) | 2006-11-21 | 2008-05-22 | Francesco Caggioni | Methods and Apparatus for Weighted Multicasting of Data Streams |
HUE060822T2 (hu) | 2006-12-29 | 2023-04-28 | Ossifi Mab Llc | Módszerek a csontnövekedés megváltoztatására SOST vagy WISE antagonista vagy agonista adásával |
MX2009008096A (es) | 2007-02-02 | 2009-08-07 | Novartis Ag | Moduladores de los componentes de enlace de esclerostatina para el tratamiento de trastornos relacionados con los huesos. |
BRPI0809026A2 (pt) * | 2007-03-20 | 2014-09-23 | Lilly Co Eli | Anticorpos antiesclerotina |
JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
CL2008002775A1 (es) | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
AR068767A1 (es) | 2007-10-12 | 2009-12-02 | Novartis Ag | Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina |
KR20100091170A (ko) | 2007-11-02 | 2010-08-18 | 노파르티스 아게 | 저밀도-지단백질 수용체-관련 단백질 6 (lrp6)을 조정하기 위한 분자 및 방법 |
EA201070740A1 (ru) | 2007-12-14 | 2010-12-30 | Эмджен Инк. | Способ лечения перелома кости антителами против склеростина |
AR072001A1 (es) | 2008-06-03 | 2010-07-28 | Abbott Lab | Inmunoglobulina con dominio variable dual y usos de la misma |
WO2010100179A2 (en) | 2009-03-05 | 2010-09-10 | Novartis Ag | Self-forming gel system for sustained drug delivery |
WO2010100200A2 (en) | 2009-03-05 | 2010-09-10 | Novartis Ag | Lyophilised antibody formulation |
WO2010115932A1 (en) | 2009-04-08 | 2010-10-14 | Novartis Ag | Combination for the treatment of bone loss |
WO2010130830A2 (en) | 2009-05-15 | 2010-11-18 | Ablynx N.V. | Amino acid sequences directed against sclerostin and polypeptides comprising the same for the treatment of bone diseases and disorders |
WO2012028683A1 (en) | 2010-09-02 | 2012-03-08 | Novartis Ag | Antibody gel system for sustained drug delivery |
CA2815181C (en) | 2010-10-27 | 2020-09-15 | William Gleason Richards | Dkk1 antibodies and methods of use |
-
2008
- 2008-09-16 CL CL2008002775A patent/CL2008002775A1/es unknown
- 2008-09-17 PL PL08832690T patent/PL2195026T3/pl unknown
- 2008-09-17 WO PCT/US2008/076679 patent/WO2009039175A2/en active Application Filing
- 2008-09-17 PL PL16162068T patent/PL3085386T3/pl unknown
- 2008-09-17 SI SI200832137T patent/SI3085386T1/sl unknown
- 2008-09-17 DK DK20174310.1T patent/DK3725329T3/da active
- 2008-09-17 CA CA2699905A patent/CA2699905C/en active Active
- 2008-09-17 LT LTEP16162068.7T patent/LT3085386T/lt unknown
- 2008-09-17 FI FIEP20174310.1T patent/FI3725329T3/fi active
- 2008-09-17 EP EP12180292.0A patent/EP2556841B9/en not_active Revoked
- 2008-09-17 EP EP20174310.1A patent/EP3725329B1/en active Active
- 2008-09-17 PT PT161620687T patent/PT3085386T/pt unknown
- 2008-09-17 HU HUE16162068A patent/HUE050653T2/hu unknown
- 2008-09-17 CA CA3170836A patent/CA3170836A1/en active Pending
- 2008-09-17 LT LTEP20174310.1T patent/LT3725329T/lt unknown
- 2008-09-17 PT PT201743101T patent/PT3725329T/pt unknown
- 2008-09-17 DK DK08832690.5T patent/DK2195026T3/da active
- 2008-09-17 SI SI200831170T patent/SI2195026T1/sl unknown
- 2008-09-17 EP EP23219258.3A patent/EP4335510A2/en active Pending
- 2008-09-17 US US12/212,327 patent/US8017120B2/en active Active
- 2008-09-17 DK DK12180292.0T patent/DK2556841T3/en active
- 2008-09-17 PT PT88326905T patent/PT2195026E/pt unknown
- 2008-09-17 AU AU2008302313A patent/AU2008302313C1/en active Active
- 2008-09-17 ES ES12180292.0T patent/ES2581754T3/es active Active
- 2008-09-17 TW TW097135666A patent/TWI526222B/zh active
- 2008-09-17 EP EP16162068.7A patent/EP3085386B1/en not_active Revoked
- 2008-09-17 PT PT121802920T patent/PT2556841T/pt unknown
- 2008-09-17 ES ES16162068T patent/ES2815677T3/es active Active
- 2008-09-17 DK DK16162068.7T patent/DK3085386T3/da active
- 2008-09-17 SI SI200832217T patent/SI3725329T1/sl unknown
- 2008-09-17 JP JP2010525108A patent/JP5643094B2/ja active Active
- 2008-09-17 AR ARP080104044A patent/AR068471A1/es not_active Application Discontinuation
- 2008-09-17 TW TW104134720A patent/TWI612972B/zh active
- 2008-09-17 PL PL12180292.0T patent/PL2556841T3/pl unknown
- 2008-09-17 ES ES08832690.5T patent/ES2445792T3/es active Active
- 2008-09-17 HU HUE12180292A patent/HUE030168T2/en unknown
- 2008-09-17 SI SI200831663A patent/SI2556841T1/sl unknown
- 2008-09-17 EP EP08832690.5A patent/EP2195026B1/en active Active
- 2008-09-17 LT LTEP12180292.0T patent/LT2556841T/lt unknown
- 2008-09-17 MX MX2010002971A patent/MX2010002971A/es active IP Right Grant
-
2011
- 2011-04-19 US US13/090,058 patent/US8329176B2/en active Active
- 2011-04-19 US US13/090,075 patent/US8440193B2/en active Active
-
2013
- 2013-04-11 US US13/860,954 patent/US9089553B2/en active Active
- 2013-08-12 HK HK13109416.2A patent/HK1182017A1/zh unknown
-
2014
- 2014-02-18 HR HRP20140153AT patent/HRP20140153T1/hr unknown
- 2014-03-07 CY CY20141100183T patent/CY1114961T1/el unknown
- 2014-09-03 JP JP2014178609A patent/JP5764704B2/ja active Active
-
2015
- 2015-06-16 US US14/740,838 patent/US10273293B2/en active Active
-
2016
- 2016-07-14 HR HRP20160872TT patent/HRP20160872T1/hr unknown
- 2016-07-15 CY CY20161100685T patent/CY1117908T1/el unknown
-
2017
- 2017-10-27 AR ARP170103001A patent/AR109995A2/es unknown
-
2018
- 2018-11-14 US US16/191,068 patent/US11091537B2/en active Active
-
2020
- 2020-09-02 CY CY20201100823T patent/CY1123463T1/el unknown
- 2020-09-09 HR HRP20201438TT patent/HRP20201438T1/hr unknown
-
2021
- 2021-07-15 US US17/376,304 patent/US20210340236A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1117908T1 (el) | Μεθοδος αναστολης επαναρροφησης οστου | |
ATE366112T1 (de) | Verwendung von zoledronsäure zur schmerzbehandlung | |
MX2021005011A (es) | Métodos de tratamiento del cáncer en pacientes identificados por biomarcadores con inhibidores no covalentes de cinasa 7 dependiente de ciclina (cdk7). | |
CY1113167T1 (el) | Ανθρωπινα anti-ngf εξουδετερωτικα αντισωματα ως εκλεκτικοι αναστολεις μονοπατιου ngf | |
MX2010006519A (es) | Metodo para tratar una fractura de hueso con anticuerpos anti-esclerostina. | |
PL379983A1 (pl) | Sposoby leczenia bólu polegające na podaniu antagonisty czynnika wzrostu nerwów i niesteroidowego leku przeciwzapalnego oraz zawierające je kompozycje | |
DE69815090D1 (de) | Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen | |
BR0307522A (pt) | Utilização de um inibidor de lipoxigenase-15 para a manufatura de um medicamento, métodos para tratamento e prevenção e kit para o diagnóstico de predisposição à perda óssea | |
ATE362363T1 (de) | Verwendung von tnf-alpha inhibitoren zur behandlung von nervenwurzelschäden | |
RU2013131640A (ru) | Способы мониторинга модуляции киназной активности рецептора фактора роста фибробластов и применения указанных способов | |
TW200616621A (en) | Use of alk 5 inhibitors to modulate or inhibit myostatin activity leading to increased lean tissue accretion in animals | |
EP2127687A4 (en) | COMPOSITION FOR THE TREATMENT OF CARTILAGE DISEASE | |
EA200900203A1 (ru) | Избирательные модуляторы рецептора андрогенов, их аналоги, производные и применение | |
CY1111786T1 (el) | Βιταμινη κ για την προληψη και τη θεραπευτικη αντιμετωπιση του δερματικου εξανθηματος μετα απο anti-egfr θεραπεια | |
ATE504600T1 (de) | Verwendung von antikörpern gegen tweak zur behandlung von schlaganfall | |
BR112021021713A2 (pt) | Método de tratamento de câncer ou inibição do crescimento de um tumor | |
FI20060246A0 (fi) | Uusi kasvua stimuloiva proteiini ja sen käyttö | |
JP2014531020A5 (el) | ||
DE60309887D1 (de) | Kombination von einem aromatasehemmer mit einem bisphosphonat | |
TW200806319A (en) | GDF-9/BMP-15 modulators for the treatment of bone disorders | |
DE602007010459D1 (de) | Verwendung von Verbindungen, die die EF-Tu-Nucleolin Wechselwirkung vehindern, zur Verhinderung oder Behandlung von Tularämie | |
MX2021005905A (es) | Metodo seguro y eficaz para tratar la psoriasis con el anticuerpo especifico anti-il-23. | |
ATE537838T1 (de) | Kombinationstherapie mit kloretazin(tm) | |
PT1401455E (pt) | Utilizacao de um adsorvente de fosfato para combater doencas vasculares | |
GB0417366D0 (en) | Method for determining the selectivity of a pre-synaptic neuromuscular blocking substance |